October 21, 2016 11:54 AM ET


Company Overview of MORPHOTEK INC.

Company Overview

MORPHOTEK INC. researches and develops a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of ovarian cancer, nonsmall cell lung cancer, melanoma, colorectal carcinoma, sarcoma, mesothelioma, inflammatory disease, and rheumatoid arthritis. The company’s products pipeline includes Farletuzumab, an investigational humanized IgG1 antibody that targets folate receptor alpha; Amatuximab, an investigational chimeric IgG1 antibody that targets mesothelin; Ontuxizumab, an investigational monoclonal antibody that recognizes endosialin; MORAb-022, an investigational human IgG1 monoclonal antibody that is investigated for its potential in the treatment of various inflam...

210 Welsh Pool Road

Exton, PA 19341

United States

Founded in 1999





Key Executives for MORPHOTEK INC.

Co-Founder, Chief Executive Officer, President and Director
Age: 50
Co-Founder, Chief Scientific Officer and Senior Vice President of Research & Development
Chief Finance Officer and Vice President of Project Management
Vice President of Pilot Plant Operations
Compensation as of Fiscal Year 2016.

MORPHOTEK INC. Key Developments

Morphotek and Eurofarma Laboratrios S.A. Signs Exclusive Licensing Agreement for Farletuzumab in Latin

Morphotek Inc. announced that it signed an exclusive licensing agreement with Eurofarma Laboratrios S.A. (Eurofarma) to develop and commercialize farletuzumab (MORAb-003) in Latin America. In exchange, Morphotek will receive an upfront payment, scheduled development and sales milestone payments, and other fees. Additionally, Morphotek will receive royalties from commercial sales of farletuzumab in Latin America. Morphotek will supply Eurofarma with clinical and commercial materials at an agreed-upon transfer price; Eurofarma has the option to assume responsibility for filling and labeling farletuzumab vials. Morphotek retains all rights to develop and commercialize farletuzumab in regions outside of Latin America. Farletuzumab is an investigational, humanized, monoclonal antibody that binds to folate receptor alpha (FRA), which is highly expressed in epithelial cancers, such as ovarian, but mostly absent from normal tissue. Farletuzumab is currently being studied in a randomized, placebo-controlled, double-blind clinical trial (NCT02289950), MORAb-003-011, in first-relapsed, platinum-sensitive ovarian cancer patients with low levels of the immunosuppressive CA125 tumor antigen. The study is designed to investigate the efficacy and safety of farletuzumab in combination with standard chemotherapy in a specific subset of patients that may be more responsive to farletuzumab based on analysis of the recently concluded Phase 3 study.

Morphotek Enters into Sponsored Research Agreement with Fox Chase Cancer Center

Morphotek reported that it entered into a Sponsored Research Agreement (SRA) with Fox Chase Cancer Center (FCCC) to expand its research efforts into the immunosuppressive effects elicited by tumor shed antigens on the efficacy of immune-based therapies. The collaboration will utilize primary human organoid cultures derived from various cancer types using optimized assays developed by ongoing research in the laboratory of Dr. Wafik El-Deiry, Deputy Cancer Center Director, Translational Research Program and Co-Leader, Molecular Therapeutics Program at FCCC. The research will focus on expanding knowledge of the biological pathways involved in suppressing patients' immune responses to tumors prior to and during immune-based therapeutic exposure. These efforts aim to identify tumor molecular and cellular signatures that can aid in identifying patients who may respond to immune-based therapies, including monoclonal antibodies targeting specific tumor cell surface antigens.

Morphotek Announces Publication of Phase 3 Results from MORAb-003-004 Trial in Platinum-Sensitive Ovarian Cancer Patients

Morphotek Inc. announced that the results from the Phase 3 MORAb-003-004 trial were recently published in the Journal of Clinical Oncology. The MORAb-003-004 clinical trial (also known as FAR-131) was a randomized, double-blind, placebo-controlled, Phase 3, global study of the safety and efficacy of weekly farletuzumab (MORAb-003) in combination with a platinum standard chemotherapy regimen (carboplatin plus taxane) in platinum-sensitive ovarian cancer patients in first relapse. Farletuzumab is an investigational, humanized, monoclonal antibody that binds to folate receptor alpha (FRA), which is highly expressed in epithelial cancers, such as ovarian, but mostly absent from normal tissue. All subjects received carboplatin plus paclitaxel or docetaxel (for six cycles combined with randomized test product 1:1:1 farletuzumab 1.25 mg/kg, farletuzumab 2.5 mg/kg, or placebo), and single-agent test product was continued weekly until disease progression. Neither farletuzumab dose met the study's primary progression-free survival (PFS) endpoint when compared to placebo, with PFS of 9.0, 9.5 (hazard ratio [HR] = 0.99) and 9.7 months (HR = 0.86) for the placebo, farletuzumab 1.25 mg/kg, and farletuzumab 2.5 mg/kg arms, respectively. There was no difference in overall survival. Prespecified subgroup analyses demonstrated that subjects with a low CA125 level (less than three times the upper limit of normal) correlated with longer PFS (HR=0.49) and OS (HR=0.44) for farletuzumab 2.5 mg/kg versus placebo. Subjects with higher farletuzumab exposure also showed superior PFS and OS compared to placebo. CA125 is a tumor-produced protein elevated in the blood of some ovarian cancer patients that has been previously reported to reduce natural killer (NK) cell function; therefore, higher CA125 levels may interfere with the immune response associated with farletuzumab's potential activity. The most common adverse events were those known to be associated with chemotherapy, including: alopecia; nausea; neutropenia; fatigue; thrombocytopenia; and neuropathy. Based on the encouraging results from the prespecified subgroup analyses, Morphotek has initiated a Phase 2 trial, MORAb-003-011, to further investigate the potential clinical benefit observed in the MORAb-003-004 patients with a low CA125 level. This global study will assess the safety and efficacy of farletuzumab, using a modified dosing schedule guided by exposure-response analysis from the Phase 3 study, in combination with a platinum doublet in first-relapsed, platinum-sensitive ovarian cancer patients with low CA125 blood levels.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MORPHOTEK INC., please visit www.morphotek.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.